+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-24Number of Pages: 152

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market (Marker Type - Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, and Oxidative Stress Biomarkers; End User - Contract Research Organizations (CRO) and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market      

Chapter 4. Market Overview
4.1. Introduction
     4.1.1. Marker Type Definition
     4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
     4.4.1. Drivers
     4.4.2. Restraints
     4.4.3. Opportunities
     4.4.4. Trends
4.5. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, 2016 – 2024
     4.5.1. Pricing – Actuals and Projections, 2016-2024 (US$)
     4.5.2. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Value Chain Analysis
4.8. Market Outlook

Chapter 5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
5.1. Introduction & Definition
5.2. Key Trends
5.3. Comparison Matrix
5.4. Market Size (US$ Mn) Forecast By Marker Type
     5.4.1. Serum Biomarkers
     5.4.2. Hepatic Fibrosis Markers
     5.4.3. Oxidative Stress Markers
     5.4.4. Apoptosis Markers
     5.4.5. Others (miRNA, carbon isotopes)
5.5. Market Attractiveness By Marker Type  

Chapter 6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Comparison Matrix
6.5. Market Size (US$ Mn) Forecast By End User
     6.5.1. Contract Research Organizations / pharmaceutical industry
     6.5.2. Academic Research Institute
     6.5.3. Hospitals
     6.5.4. Diagnostic Laboratories
6.6. Market Attractiveness By End User  

Chapter 7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Key Trends
7.3. Market Size (US$ Mn) Forecast By Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific 
     7.3.5. Middle East and Africa
7.4. Market Attractiveness By Region

Chapter 8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Marker Type
     8.4.1. Serum Biomarkers
     8.4.2. Hepatic Fibrosis Markers
     8.4.3. Oxidative Stress Markers
     8.4.4. Apoptosis Markers
     8.4.5. Others (miRNA, carbon isotopes)
8.5. Market Size (US$ Mn) Forecast By End User
     8.5.1. Contract Research Organizations / pharmaceutical industry
     8.5.2. Academic Research Institute
     8.5.3. Hospitals
     8.5.4. Diagnostic Laboratories
8.6. Market Size (US$ Mn) Forecast, By Country
     8.6.1. U.S.
     8.6.2. Canada
8.7. Market Attractiveness Analysis 
     8.7.1. By Marker Type
     8.7.2. By End User
     8.7.3. By Country

Chapter 9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Marker Type
     9.4.1. Serum Biomarkers
     9.4.2. Hepatic Fibrosis Markers
     9.4.3. Oxidative Stress Markers
     9.4.4. Apoptosis Markers
     9.4.5. Others (miRNA, carbon isotopes)
9.5. Market Size (US$ Mn) Forecast By End User
     9.5.1. Contract Research Organizations / pharmaceutical industry
     9.5.2. Academic Research Institute
     9.5.3. Hospitals
     9.5.4. Diagnostic Laboratories
9.6. Market Size (US$ Mn) Forecast, By Country
     9.6.1. U.K.
     9.6.2. France
     9.6.3. Germany
     9.6.4. Spain
     9.6.5. Rest of Europe
9.7. Market Attractiveness Analysis 
     9.7.1. By Marker Type
     9.7.2. By End User
     9.7.3. By Country 

Chapter 10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings / Developments
10.3. Key Trends
10.4. Market Size (US$ Mn) Forecast By Marker Type
     10.4.1. Serum Biomarkers
     10.4.2. Hepatic Fibrosis Markers
     10.4.3. Oxidative Stress Markers
     10.4.4. Apoptosis Markers
     10.4.5. Others (miRNA, carbon isotopes)
10.5. Market Size (US$ Mn) Forecast By End User
     10.5.1. Contract Research Organizations / pharmaceutical industry
     10.5.2. Academic Research Institute
     10.5.3. Hospitals
     10.5.4. Diagnostic Laboratories
10.6. Market Size (US$ Mn) Forecast, By Country
     10.6.1. Japan
     10.6.2. China
     10.6.3. India
     10.6.4. Rest of APAC
10.7. Market Attractiveness Analysis 
     10.7.1. By Marker Type
     10.7.2. By End User
     10.7.3. By Country 

Chapter 11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
11.1. Introduction
11.2. Key Findings / Developments
11.3. Key Trends
11.4. Market Size (US$ Mn) Forecast By Marker Type
     11.4.1. Serum Biomarkers
     11.4.2. Hepatic Fibrosis Markers
     11.4.3. Oxidative Stress Markers
     11.4.4. Apoptosis Markers
     11.4.5. Others (miRNA, carbon isotopes)
11.5. Market Size (US$ Mn) Forecast By End User
     11.5.1. Contract Research Organizations / pharmaceutical industry
     11.5.2. Academic Research Institute
     11.5.3. Hospitals
     11.5.4. Diagnostic Laboratories
11.6. Market Size (US$ Mn) Forecast, By Country
     11.6.1. Brazil
     11.6.2. Mexico
     11.6.3. Argentina
     11.6.4. Rest of Latin America
11.7. Market Attractiveness Analysis 
     11.7.1. By Marker Type
     11.7.2. By End User
     11.7.3. By Country 

Chapter 12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
12.1. Introduction
12.2. Key Findings / Developments
12.3. Key Trends
12.4. Market Size (US$ Mn) Forecast By Marker Type
     12.4.1. Serum Biomarkers
     12.4.2. Hepatic Fibrosis Markers
     12.4.3. Oxidative Stress Markers
     12.4.4. Apoptosis Markers
     12.4.5. Others (miRNA, carbon isotopes)
12.5. Market Size (US$ Mn) Forecast By End User
     12.5.1. Contract Research Organizations / pharmaceutical industry
     12.5.2. Academic Research Institute
     12.5.3. Hospitals
     12.5.4. Diagnostic Laboratories
12.6. Market Size (US$ Mn) Forecast, By Country
     12.6.1. South Africa
     12.6.2. GCC Countries
     12.6.3. Rest of MEA
12.7. Market Attractiveness Analysis 
     12.7.1. By Marker Type
     12.7.2. By End User
     12.7.3. By Country 

Chapter 13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
     13.2.1. BioPredictive S.A.S
             13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.1.2. Product Portfolio
             13.2.1.3. SWOT Analysis
             13.2.1.4. Strategic Overview
     13.2.2. One Way Liver S.L.
             13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.2.2. Product Portfolio
             13.2.2.3. SWOT Analysis
             13.2.2.4. Strategic Overview
     13.2.3. Genfit SA
             13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.3.2. Product Portfolio
             13.2.3.3. SWOT Analysis
             13.2.3.4. Financial Overview
             13.2.3.5. Strategic Overview
     13.2.4. Quest Diagnostics Incorporated
             13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.4.2. Product Portfolio
             13.2.4.3. SWOT Analysis
             13.2.4.4. Financial Overview
             13.2.4.5. Strategic Overview
     13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
             13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.5.2. Product Portfolio
             13.2.5.3. SWOT Analysis
             13.2.5.4. Financial Overview
             13.2.5.5. Strategic Overview
     13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
             13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.6.2. Product Portfolio
             13.2.6.3. SWOT Analysis
             13.2.6.4. Financial Overview
             13.2.6.5. Strategic Overview
     13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
             13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.7.2. Product Portfolio
             13.2.7.3. SWOT Analysis
             13.2.7.4. Financial Overview
             13.2.7.5. Strategic Overview
     13.2.8. Exalenz Biosciences Ltd.
             13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.8.2. Product Portfolio
             13.2.8.3. SWOT Analysis
             13.2.8.4. Financial Overview
             13.2.8.5. Strategic Overview

Chapter 14. Key Take Away

List of Figures

Figure 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Market Type, 2017 and 2024
Figure 03: Global Serum Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 04: Global Hepatic Fibrosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2024
Figure 05: Global Apoptosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 06: Global Oxidative Stress Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 07: Global other Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 08: Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 09: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End-user, 2017 and 2024
Figure 10: Global CRO / Pharmaceutical Industry Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 11: Global Academic Research Institute Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 12: Global Hospital Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 13: Global Diagnostic Laboratories Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 14: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End-user
Figure 15: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Region, 2017 and 2024 
Figure 16: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Region
Figure 17: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 18: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 19: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 20: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 21: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 22: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 23: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 24: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 25: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 26: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 27: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 28: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 29: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 30: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 31: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024 
Figure 32: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 33: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 34: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 35: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 36: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 37: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 38: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 39: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 40: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 41: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 42: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 43: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 44: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 45: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 46: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 47: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024 
Figure 48: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 49: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 50: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 51: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User

List of Tables

Table 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by End-user, 2015–2024
Table 03: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region,
Table 04: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 05: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 06: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country,
Table 07: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 08: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 09: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 10: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 11: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 12: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 13: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 14: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 15: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 16: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 
Table 17: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 18: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024


 
 
Back To Top